Astellas Pharma (4503 N) Stock Overview
Manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
4503 N Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥253.57 |
| 52 Week High | JP¥281.91 |
| 52 Week Low | JP¥253.57 |
| Beta | 0.084 |
| 1 Month Change | -10.05% |
| 3 Month Change | -10.05% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -27.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4503 N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 0.3% |
| 1Y | n/a | 23.3% | 15.7% |
Return vs Industry: Insufficient data to determine how 4503 N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4503 N performed against the MX Market.
Price Volatility
| 4503 N volatility | |
|---|---|
| 4503 N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: 4503 N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine 4503 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 13,643 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant.
Astellas Pharma Inc. Fundamentals Summary
| 4503 N fundamental statistics | |
|---|---|
| Market cap | Mex$443.04b |
| Earnings (TTM) | Mex$31.77b |
| Revenue (TTM) | Mex$233.11b |
Is 4503 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4503 N income statement (TTM) | |
|---|---|
| Revenue | JP¥2.14t |
| Cost of Revenue | JP¥408.43b |
| Gross Profit | JP¥1.73t |
| Other Expenses | JP¥1.44t |
| Earnings | JP¥291.54b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 162.73 |
| Gross Margin | 80.91% |
| Net Profit Margin | 13.63% |
| Debt/Equity Ratio | 30.9% |
How did 4503 N perform over the long term?
See historical performance and comparisonDividends
Does 4503 N pay a reliable dividends?
See 4503 N dividend history and benchmarks| Astellas Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Jun 03 2026 |
| Days until Ex dividend | 55 days |
| Days until Dividend pay date | 10 days |
Does 4503 N pay a reliable dividends?
See 4503 N dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 13:00 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Astellas Pharma Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |